New oxaliplatin-based combinations in the treatment of colorectal cancer

Colorectal Disease

Volumn 5, Issue SUPPL. 3, 2003, Pages 1-9

  Cassidy, J ^a   Hochster, H ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Biological therapy; C225; Capecitabine; Colorectal cancer; Combination therapy; Iressa; Irinotecan; Oxaliplatin

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PEMETREXED; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR; UFT; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CELL ADHESION; CELL DIFFERENTIATION; CELL MOTILITY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; LIVER METASTASIS; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 0345688690     PISSN: 14628910     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1318.5.s3.2.x     Document Type: Article

References (57)

1. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil/leucovorin as the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 137-47.
2. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2398-947.
3. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-9.
4. Adam R. (2000) Surgery of liver metastases from colorectal cancer. Surgeon viewpoint. ESMO, Hamburg, oral communication.
5. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25 (Suppl. 5): 4-12.
6. McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs 2001; 61: 2309-26.
7. Hoff PM, Pazdur R, Benner SE, Canetta R. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 1998; 9: 479-90.
8. Van Cutsem E, Twelves C, Cassidy J et al. from the Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil Plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-106.
9. Diaz-Rubio E, Evans TR, Tabemero J et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002; 13: 558-65.
10. Zeuli M, Costanzo ED, Sdrobolini A et al. from Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC) and Gruppo Oncologico Laziale (GOL). Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. Ann Oncol 2001; 12: 1737-41.
11. Borner MM, Dietrich D, Stupp R et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20: 1759-66.
12. Tabernero J, Butts CA, Cassidy J et al. Capecitabine and oxaliplatin in combination (Xelox) as first line therapy for patients with metastatic colorectal cancer (MCRC): results of an international multicenter phase II trial. Proc Am Soc Clin Oncol 2002; 21: 133a (Abstract 531).
13. Douillard J-Y, Seitz JF. A phase I study of oral uracil/tegafur (UFT) plus leucovorin (LV) combined with oxaliplatin in patients with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2001; 20: 144a (Abstract 572).
14. Garcia-Alfonso P, Perez-Manga G, Mendez M et al. Tomudex + oxaliplatin + UFT as first-line treatment for metastatic colorectal cancer. Efficacy Security Proc Am Soc Clin Oncol 2002; 21: 170a (Abstract 676).
15. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19: 1501-18.
16. Khayat D, Gil-Delgado M, Antoine EC, Nizri D, Bastian G. The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Oncology (Huntingt) 2001; 15: 415-29.
17. Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999; 5: 1189-96.
18. Scheithauer W, Kornek GV, Raderer M et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pre-treated colorectal cancer. J Clin Oncol 1999; 17: 902-6.
19. Kretzschmar A, Thuss-Patientce PC, Pink D et al. Weekly combination of oxaliplatin (OX) and irinotecan (IRI) in 5-FU resistant colorectal cancer (CRC). European J Cancer 2001; 36 (Suppl. 6): Abstract 1075.
20. Rougier P, Lepille D, Douillard J et al. Final results of a randomised phase II study of three combinations: CPT-11 + LV5FU2, LOHP + LV5FU2, and CPT-11 + LOHP in 5-FU resistant advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2001; 20: 142a (Abstract 566).
21. Kemeny NE, Tong W, DiLauro C, Teitcher J, Gonen M, Sltz L. Phase I/II trial of weekly oxaliplatin and irinotecan (CPT-11) in previously treated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2001; 20: 133a (Abstract 529).
22. Scheithauer W, Kornek GV, Ulrich-Pur H. Irinotecan (CPT-11) plus oxaliplatin (L-OHP) in advanced colorectal cancer (ACC): a randomized phase II study. Proc Am Soc Clin Oncol 2001; 21: 135a (Abstract 538).
23. Scheithauer W, Kornek GV, Ulrich-Pur H et al. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial. Cancer 2001; 91: 1264-71.
24. Scheithauer W, Kornek GV, Raderer M et al. Randomized Multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 2002; 20: 165-72.
25. Cascinu S, Graziano F, Ferrau F et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GIS-CAD). Ann Oncol 2002; 13: 716-20.
26. Comella P, Casaretti R, Crucitta E et al. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil I.V. bolus: a salvage regimen for colorectal cancer patients. Br J Cancer 2002; 86: 1871-5.
27. Van Cutsem E, Van Laethem J, Dirix L et al. Phase II study of raltitrexed in combination with oxaliplatin as second line treatment in refractory advanced colorectal cancer. Eur J Cancer 2001; 36 (Suppl. 6). (Abstract 1008).
28. Scheithauer W, Kornek GV, Brugger S et al. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pre-treated colorectal cancer. Cancer Invest, 2002; 20: 60-8.
29. Hejna M, Kostler WJ, Raderer M et al. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. Anticancer Drugs 2000; 11: 629-34.
30. Workman P, Kaye S (eds). A Trends guide to cancer therapeutics. Trends Mol Med 2002; 8 (4 Suppl.): S1-S73.
31. de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 2002; 8: S19-S26.
32. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 (Suppl. 4): S3-S8.
33. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-70.
34. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
35. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78: 1284-92.
36. Chow NH, Liu HS, Lee EI et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 1997; 17: 1293-6.
37. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992; 13: 3-17.
38. Bucci B, D'Agnano I, Botti C et al. EGF-R expression in ductal breast cancer. proliferation and prognostic implications. Anticancer Res 1997; 17: 769-74.
39. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999; 53: 167-76.
40. Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998; 37: 285-9.
41. ImClone Systems Incorporated New York. NY. data on file., 2002.
42. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001; 37 (Suppl. 4): S16-S22.
43. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6: 2166-74.
44. Prewitt M, Hooper A, Bassi R, Ellis LM, Waksal H, Hicklin DJ. Growth inhibition of human colorectal carcinoma xenografts by anti-EGF receptor monoclonal antibody IMC-C225 in combination with 5-fluorouracil or irinotecan. Proc Am Ass Can Res 2001; 42: 287 (Abstract 1543).
45. Saleh MN, Raisch KP, Stackhouse MA et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 1999; 14: 451-63.
46. Saltz L, Rubin M, Hochster H et al. Cetuximab (IMC-C225) Plus CPT-11 is Active in CPT-11-Refractory Colorectal Cancer that Expresses Epidermal Growth Factor Receptor (EGFR). Proc Am Soc Clin Oncol 2001; 21: 3a (Abstract 7).
47. Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 2001; 7: 4436s-4442s.
48. Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 2001; 13: 491-8.
49. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2) -overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61: 8887-95.
50. Hidalgo M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Therapeutic angiogenesis inhibitors in the treatment of cancer. Adv Intern Med 2001; 47: 159-90.
51. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001; 26: 25-35.
52. Cross MJ. Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22: 201-7.
53. Rosen LS. Clinical experience with angiogenesis signaling inhibitors. Focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002; 9: 36-44.
54. Bergsland E, Hurwitz H, Fehrenbacher L et al. A randomized phase II trial comparing rhuMAB VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluoroucil/leucovorin (FU/LV) alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 242a (Abstract 939).
55. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002; 8 (4 Suppl.): S49-S54.
56. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 2002; 6: 493-500.
57. Cusack JC Jr, Liu R, Houston M et al. Enhanced chemo-sensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappa B inhibition. Cancer Res 2001; 61: 3535-40.